Ironwood Pharmaceuticals, Inc.

NasdaqGS:IRWD Rapporto sulle azioni

Cap. di mercato: US$669.3m

Ironwood Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Ironwood Pharmaceuticals has a total shareholder equity of $-321.7M and total debt of $623.6M, which brings its debt-to-equity ratio to -193.8%. Its total assets and total liabilities are $395.6M and $717.3M respectively. Ironwood Pharmaceuticals's EBIT is $119.3M making its interest coverage ratio 4.3. It has cash and short-term investments of $105.5M.

Informazioni chiave

-193.8%

Rapporto debito/patrimonio netto

US$623.65m

Debito

Indice di copertura degli interessi4.3x
ContantiUS$105.52m
Patrimonio netto-US$321.73m
Totale passivitàUS$717.35m
Totale attivitàUS$395.62m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Oct 24
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Aug 16
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Jun 27
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 20

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19
Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18
An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28
These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Jul 29

Analisi della posizione finanziaria

Passività a breve termine: IRWD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Passività a lungo termine: IRWD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: IRWD has negative shareholder equity, which is a more serious situation than a high debt level.

Riduzione del debito: IRWD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Copertura del debito: IRWD's debt is well covered by operating cash flow (23.5%).

Copertura degli interessi: IRWD's interest payments on its debt are well covered by EBIT (4.3x coverage).


Bilancio


Scoprire le aziende sane